Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)
- PMID: 21095413
- DOI: 10.1016/j.mcna.2010.08.013
Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)
Abstract
Male lower urinary tract symptoms, benign prostatic hyperplasia, enlargement of the prostate, and bladder outlet obstruction are common among aging men and will increase in socioeconomic and medical importance at a time of increased life expectancy and aging of the baby boomer generation. This article reviews the epidemiology, management, and therapeutic options for these conditions. In patients bothered by moderate to severe symptoms, providers can make educated and differential choices between several classes of drugs, alone or in combination, to treat effectively and improve the symptoms in most men. Despite the efficacy of medical therapy, there will be patients who require referral to a urologist either early, to rule out prostate cancer and other conditions, or later, after initial medical therapy and lifestyle management has failed. Perhaps as many as 30% of patients fail to achieve sufficient symptom improvement with medication, lifestyle adjustment, and fluid management, and may require more invasive or surgical treatment options.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6. Prog Urol. 2012. PMID: 23178093 French.
-
Benign prostatic hyperplasia - progress in pathophysiology and management.Pol Merkur Lekarski. 2015 Nov;39(233):263-70. Pol Merkur Lekarski. 2015. PMID: 26637089
-
The role of combination medical therapy in benign prostatic hyperplasia.Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. Int J Impot Res. 2008. PMID: 19002123 Review.
-
Benign Prostatic Hyperplasia.Prim Care. 2019 Jun;46(2):223-232. doi: 10.1016/j.pop.2019.02.003. Epub 2019 Apr 1. Prim Care. 2019. PMID: 31030823 Review.
-
Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?Curr Opin Urol. 2014 Jan;24(1):21-8. doi: 10.1097/MOU.0000000000000007. Curr Opin Urol. 2014. PMID: 24231531 Review.
Cited by
-
Small prostate associated with higher incidence of detrusor underactivity and tendency of combination with bladder stone in patients with bladder outlet obstruction.Medicine (Baltimore). 2024 Nov 8;103(45):e40451. doi: 10.1097/MD.0000000000040451. Medicine (Baltimore). 2024. PMID: 39533621 Free PMC article.
-
TGFβ2 mediates oxidative stress-induced epithelial-to-mesenchymal transition of bladder smooth muscle.In Vitro Cell Dev Biol Anim. 2024 Aug;60(7):793-804. doi: 10.1007/s11626-024-00864-9. Epub 2024 Feb 26. In Vitro Cell Dev Biol Anim. 2024. PMID: 38409639 Free PMC article.
-
New therapeutic targets to prevent benign prostatic enlargement and symptomatic progression to benign prostatic obstruction-ICI-RS 2023.Neurourol Urodyn. 2024 Aug;43(6):1363-1371. doi: 10.1002/nau.25326. Epub 2023 Nov 2. Neurourol Urodyn. 2024. PMID: 37916442 Review.
-
A pilot study of stereotactic body radiotherapy combined with pelvic radiotherapy and GTVp boost based on multiparameter magnetic resonance image in patients with high-risk prostate cancer.Medicine (Baltimore). 2023 Sep 29;102(39):e35260. doi: 10.1097/MD.0000000000035260. Medicine (Baltimore). 2023. PMID: 37773877 Free PMC article.
-
Combination of Lycopene and Curcumin Synergistically Alleviates Testosterone-Propionate-Induced Benign Prostatic Hyperplasia in Sprague Dawley Rats via Modulating Inflammation and Proliferation.Molecules. 2023 Jun 21;28(13):4900. doi: 10.3390/molecules28134900. Molecules. 2023. PMID: 37446563 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
